Functionally opposing roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the regulation of cardiac contractility

Circulation

Volumn 118, Issue 16, 2008, Pages 1651-1658

  Szokodi, István ^a,b   Kerkelä, Risto ^a,c   Kubin, Anna Maria ^a   Sármán, Balázs ^d   Pikkarainen, Sampsa ^a   Kónyi, Attila ^b   Horváth, Iván G ^b   Papp, Lajos ^b   Tóth, Miklós ^d   Skoumal, Réka ^a,d   Ruskoaho, Heikki ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF PÉCS   (Hungary)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Szentágothai János Knowledge Center   (Hungary)

Author keywords

Contractility; Endothelin; Mitogen activated protein kinases; Signal transduction

Indexed keywords

ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLAMBAN; PROTEIN P90; S6 KINASE; PHOSPHOLIPASE C; PROTEIN KINASE C;

ANIMAL TISSUE; ARTICLE; HEART MUSCLE CONTRACTILITY; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; TRANSACTIVATION; ANIMAL; DRUG EFFECT; ENZYMOLOGY; HEART CONTRACTION; HEART MUSCLE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ENDOTHELIN-1; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIAL CONTRACTION; MYOCARDIUM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; TYPE C PHOSPHOLIPASES;

EID: 55949117098     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.758623     Document Type: Article

References (45)

1. Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res. 2002;91:776-781.
2. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation. 2007;116:1413-1423.
3. Clerk A, Michael A, Sugden PH. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J Cell Biol. 1998;142:523-535.
4. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 2000;19:6341-6350.
5. Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, Parsons S, Braunwart J, Glascock BJ, Klevitsky R, Kimball TF, Hewett TE, Molkentin JD. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest. 2003;111:1475-1486.
6. Wetzker R, Böhmer FD. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol. 2003;4:651-657.
7. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35-40.
8. + exchanger. Circ Res. 1991;68:269-279.
9. 2+ signalling in rabbit ventricular myocytes. Br J Pharmacol. 2000;131: 638-644.
10. 2+ signaling in contractile regulation induced by crosstalk between endothelin-1 and norepinephrine in dog ventricular myocardium. Circ Res. 2003;92:1024-1032.
11. 2+ sensitization induced by endothelin-1. Eur J Pharmacol. 2004;507:135-143.
12. Kinnunen P, Szokodi I, Nicholls MG, Ruskoaho H. Impact of NO on ET-1-and AM-induced inotropic responses: potentiation by combined administration. Am J Physiol Regul Integr Comp Physiol. 2000;279:R569-R575.
13. Szokodi I, Tavi P, Földes G, Voutilainen-Myllylä S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysä J, Tóth M, Ruskoaho H. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002;91:434-440.
14. Takeuchi Y, Kihara Y, Inagaki K, Yoneda T, Sasayama S. Endothelin-1 has a unique oxygen-saving effect by increasing contractile efficiency in the isolated rat heart. Circulation. 2001;103:1557-1563.
15. B receptors in regulation of cardiac contractile function in mice. Am J Physiol Heart Circ Physiol. 2003;285:H112-H118.
16. Zolk O, Münzel F, Eschenhagen T. Effects of chronic endothelin-1 stimulation on cardiac myocyte contractile function. Am J Physiol Heart Circ Physiol. 2004;286:H1248-H1257.
17. Bogoyevitch MA, Glennon PE, Sugden PH. Endothelin-1, phorbol esters and phenylephrine stimulate MAP kinase activities in ventricular cardiomyocytes. FEBS Lett. 1993;317:271-275.
18. Sugden PH. An overview of endothelin signaling in the cardiac myocyte. J Mol Cell Cardiol. 2003;35:871-886.
19. Szokodi I, Kinnunen P, Tavi P, Weckström M, Tóth M, Ruskoaho H. Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation. 1998;97:1062-1070.
20. Tenhunen O, Sármán B, Kerkelä R, Szokodi I, Papp L, Tóth M, Ruskoaho H. Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-induced activation of GATA-4 binding in adult heart. J Biol Chem. 2004;279: 24852-24860.
21. Fulton D, McGiff JC, Quilley J. Role of phospholipase C and phospholipase A2 in the nitric oxide-induced vasodilator effect of bradykinin in the rat perfused heart. J Pharmacol Exp Ther. 1996;278:518-526.
22. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res. 2002;90:135-142.
23. Knight DR, Smith AH, Flynn DM, MacAndrew JT, Ellery SS, Kong JX, Marala RB, Wester RT, Guzman-Perez A, Hill RJ, Magee WP, Tracey WR. A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo. J Pharmacol Exp Ther. 2001;297: 254-259.
24. Bogoyevitch MA, Glennon PE, Andersson MB, Clerk A, Lazou A, Marshall CJ, Parker PJ, Sugden PH. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes: the potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J Biol Chem. 1994;269: 1110-1119.
25. + exchanger in the rat myocardium by mitogen-activated protein kinase-dependent pathways. J Biol Chem. 1999;274:22985-22992.
26. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566-577.
27. 2+ antagonist-insensitive coronary smooth muscle contraction via activation of ε-protein kinase C. Hypertension. 2004;43:897-904.
28. Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-Leil MK, Meloche S, Pouyssegur J, Pages G, De Windt LJ, Doevendans PA, Molkentin JD. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 2004;109:1938-1941.
29. Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation. 2004;110:718-723.
30. Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, Robbins J, Molkentin JD. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA. 2007;104:14074-14079.
31. Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, Adachi S, Kitakaze M, Hashimoto K, Raab G, Nanba D, Higashiyama S, Hori M, Klagsbrun M, Mekada E Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA. 2003;100:3221-3226.
32. Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 2006;439:168-174.
33. + exchanger in the slow force response to myocardial stretch. Circ Res. 1999;85:658-660.
34. i-independent pathways. Hypertension. 2005;45: 288-293.
35. + exchanger isoform-1. J Biol Chem. 1999;274:20206-20214.
36. Richards SA, Dreisbach VC, Murphy LO, Blenis J. Characterization of regulatory events associated with membrane targeting of p90 ribosomal S6 kinase 1. Mol Cell Biol. 2001;21:7470-7480.
37. + exchanger-mediated cardiac ischemia-reperfusion injury. Circulation. 2006;113:2516-2523.
38. i-independent positive inotropic effects in failing human myocardium. Circulation. 2005;111:2588-2595.
39. 1AR-induced positive inotropic response in heart is dependent on myosin light chain phosphorylation. Am J Physiol Heart Circ Physiol. 2002;283:H1471-H1480.
40. Liao P, Wang SQ, Wang S, Zheng M, Zheng M, Zhang SJ, Cheng H, Wang Y, Xiao RP. p38 mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res. 2002;90:190-196.
41. i or Gβγ in adult mouse cardiomyocytes. J Biol Chem. 2000;275:40635-40640.
42. Bellahcene M, Jacquet S, Cao XB, Tanno M, Haworth RS, Layland J, Kabir AM, Gaestel M, Davis RJ, Fiavell RA, Shah AM, Avkiran M, Marber MS. Activation of p38 mitogen activated protein kinase contributes to the early cardiodepressant action of tumor necrosis factor. J Am Coll Cardiol. 2006;48: 545-555.
43. Liu Q, Hofmann PA. Protein phosphatase 2A-mediated cross-talk between p38 MAPK and ERK in apoptosis of cardiac myocytes. Am J Physiol Heart Circ Physiol. 2004;286:H2204-H2212.
44. Liu Q, Hofmann PA. Modulation of protein phosphatase 2a by adenosine A, receptors in cardiomyocytes: role for p38 MAPK. Am J Physiol Heart Circ Physiol. 2003;285:H97-H103.
45. Liao P, Georgakopoulos D, Kovacs A, Zheng M, Lerner D, Pu H, Saffitz J, Chien K, Xiao RP, Kass DA, Wang Y. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci USA. 2001;98:12283-12288.